Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

Davis, John C.; Heijde, Desirée van der; Braun, Jürgen; Dougados, Maxime; Cush, John J.; Clegg, Daniel O.; Kivitz, Alan; Fleischmann, Roy; Inman, Robert D.; Tsuji, Wayne

doi:10.1002/art.11325

Cited by 688 publications

(445 citation statements)

References 18 publications

Supporting

Mentioning

390

Contrasting

Unclassified

Order By: Relevance

“…Etanercept is a fully human recombinant protein, comprising two molecules of soluble TNF receptor p75 and the crystallisable fragment component of immunoglobulin G1, which speciWcally binds to and neutralizes TNF-alpha. Several clinical studies have shown that etanercept reduces disease activity in patients with spondyloarthropathies, including reactive arthritis and AS [4][5][6][7][8]. Similar results have been reported with inXiximab, a chimeric monoclonal antibody against TNF [9][10][11][12][13][14][15].…”

Section: Introductionsupporting

confidence: 53%

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

et al. 2009

View full text Add to dashboard Cite

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinXammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The eYcacy and safety of both etanercept and inXiximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a signiWcant more rapid clinical improvement in the inXiximab treated group. Treatment with both etanercept and inXiximab at the end of the study was eVective, safe, and well tolerated.

show abstract

Section: Introductionsupporting

confidence: 53%

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

et al. 2009

View full text Add to dashboard Cite

show abstract

“…These were followed by more stringent trials of INF [26][27][28][29][30], ETA [31][32][33][34], and most recently ADA [35], enrolling over 1000 patients with ankylosing spondylitis. These trials are summarized in Table 3.…”

Section: Adamentioning

confidence: 99%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

“…According to the meta-analysis of randomized-controlled trials (RCTs), it became evident that all available TNFi-s (adalimumab, etanercept, infliximab and golimumab) exert similar effects on signs and symptoms of the axial components of the disease (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis

et al. 2014

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate efficacy, reasons for switching and drug survival of TNF-α inhibitors (TNFi-s) used as first and second line drugs in ankylosing spondylitis (AS).Methods: Data of patients suffering from AS and treated with at least one TNFi between November 2005 and November 2013 were extracted retrospectively from the database of one clinical center. Beside demographic data, the disease activity measured by BASDAI, the response rates (BASDAI50), reasons for switching and survival curves of TNFi-s were analyzed in general and in subgroups of patients treated with each of the available TNFi-s. The reasons for switching were defined as inefficacy, side effect of the given drug, patient's request, and occurence of extra-articular manifestations.Results: Altogether 175 patients were on TNFi and 77 of them received at least 2 TNFi-s. The patients' age at the initiation of the first TNFi was higher among switchers compared to nonswitchers (42.5±12.6 vs 38.8±11.2 years, p=0.049), otherwise gender, disease duration and initial disease activity had no influence on the risk of switching. The decrease of BASDAI was similar among non-switchers and switchers either using the first or second TNFi, but the response rates to the first and second TNFi were worse in switchers than in non-switchers. Following the failure of first TNFi, the retention on therapy was unfavourable, especially in patients on infliximab after one year of treatment. The main reason for switching from the first drug was inefficacy. The frequency of side effects that led to switching was higher in the infliximab group than in patiets treated with other agents. Conclusion:Although the retention rate to a second line TNFi was somewhat worse than that to the first line TNFi, switching of TNFi-s is a good therapeutic option is AS patients who failed to respond to the first TNFi.

show abstract

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial

Cited by 688 publications

References 18 publications

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

TNFα blockade in human diseases: An overview of efficacy and safety

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis

Contact Info

Product

Resources

About